Pharma & Bio
Technology
Kim Deok-kyu, CEO of GeronCellVein: "We’re Revolutionizing the PDRN Market with Low-Temperature Extraction Technology... Aiming for an IPO Next Year"
“Extraction at high temperatures inevitably causes DNA damage. We have dramatically improved safety by maintaining a consistent molecular weight—like a fingerprint—through low-temperature extraction a…
Lifestyle
Psomagen, Inc. Clears the ‘Most Demanding’ New York Clinical Testing Hurdle… Begins Full-Scale Push into the Genomic Diagnostics Market
Psomagen, Inc.(950200)has secured certification from the New York State Department of Health, which is considered a key gateway to the U.S. genomic diagnostics market. This achievement is seen as layi…
Technology
Antrogen Slides on Japan Fears, Hanmi Science Gains [K-Bio Pulse]
South Korean biopharmaceutical stocks moved in opposite directions on Tuesday, with Antrogen tumbling to the daily limit amid concerns over the commercial potential of its regenerative medicine produc…
Technology
ANTEROGEN CO., LTD. Hits ‘Daily Lower Limit’; “25 Patients in Japan Is an Initial Estimate”… Hanmi Science Soars Amid ‘Control Dispute’ [Bio Spotlight]
On the 8th, in the domestic pharmaceutical and biotech stock market, ANTEROGEN CO., LTD.(065660)plummeted to its daily price limit amid concerns over its market potential in Japan, while Hanmi Science…
Technology
With Latuda’s Indications Expanding and Synergies with Union Pharmaceutical… Will BukwangPharmaceutical’s Enterprise Value Be Reevaluated?
BukwangPharmaceutical(003000)is kicking off a revaluation of its corporate value, driven by the expanded indication for its key new drug “Latuda” for depression and the synergies from its acquisition …
Business·Industry
[Exclusive] Peptron, Inc.’s Hopes for ‘Once-a-Month Mounjaro’ Shaken; “No Terzepatide in Joint Research with Lilly”
Choi Ho-il, CEO of Peptron, Inc. (Photo: E-Daily DB Inc.)
“In our joint research with Company L, we are developing an entirely different peptide formulation together, and Tuzepatide is not include…
Business·Industry
Amicogen, Inc. Faces Controversy Over Transfer of Management Control to Newly Established Subsidiary via 10 Billion Won Capital Increase… “Explanation to Follow After Payment”
There is widespread speculation in the industry regarding Amicogen, Inc.(092040)’s plan to transfer management control to a newly established entity through a 10 billion won third-party private placem…
Lifestyle
NEXTBIOMEDICAL CO., LTD. to Launch New Clinical Trial for ‘Nexphere F’... ‘Unlimited Expansion of Embolization Platform Draws Attention’
Innovative biomedicine company #NEXTBIOMEDICAL CO., LTD. is leading a paradigm shift in the medical device market with “Nexsphere-FTM,” a treatment for knee osteoarthritis developed in-house. Building…
Lifestyle
"The Era of Adopting Good Technology Is Over"... DaewonPharmaceutical's Open Innovation Approach Through Partnerships with ILDONG PHARM, Tium, and Farmus
“In the past, bringing in good technology was what gave us a competitive edge. Things are different now. The real competitive edge lies in how successfully we develop the technology we’ve brought in.”…
Venture
"Composed of Over 100 Doctors": Which K-Bio Company Has Caught Ad Partners' Attention?
The private investment consortium Ad Partners consists of about 100 members. Whenever an investment opportunity arises in a promising company, Ad Partners forms a private project fund with 49 or fewer…